Compare Amylx Pharmaceuticals Inc (AMLX) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Kimberly Clark Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Kimberly Clark Corp trades at $112.58 (market cap $37.31B). The key difference: Kimberly Clark Corp is far larger — about 18.8× Amylx Pharmaceuticals Inc's market cap, and Kimberly Clark Corp pays a 4.55% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KMB | |
|---|---|---|
Market Cap | $1.98B | $37.31B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $136.77 |
52-Week Low | $7.64 | $93.05 |
Enterprise Value | $1.70B | $43.86B |
Dividend Yield | — | 4.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Kimberly-Clark (KMB) trades at $112.41, up 2.26% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company maintains strong profitability with a 12.8% net income margin and a high ROE of 146.29%, though revenue declined to $16.45B in 2025. Recent news highlights its dividend reliability and upcoming Q2 2026 results announcement on August 4, 2026.
KMB offers a stable dividend yield and defensive appeal, but faces headwinds from revenue pressure and high valuation multiples. Analyst consensus is mixed with a $109 price target below the current price, suggesting cautious optimism. Key risks include consumer sentiment impacts and input cost inflation, requiring monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
